STOCK TITAN

ProKidney (PROK) Stock News

PROK NASDAQ

ProKidney Corp. develops rilparencel, also described as REACT or Renal Autologous Cell Therapy, as an autologous cell therapy candidate for patients with advanced chronic kidney disease and diabetes. News about PROK centers on clinical data from REGEN-007, Phase 3 PROACT 1/REGEN-006 development, regulatory interactions with the FDA on the use of eGFR slope in an accelerated approval pathway, and scientific presentations in nephrology forums.

Company updates also cover quarterly and annual financial results, cash runway commentary, investor conference participation, and leadership additions tied to commercial planning for rilparencel.

Rhea-AI Summary

ProKidney (Nasdaq: PROK) reported third-quarter financial results and maintained its target for pivotal Phase 3 rilparencel results in Q2 2027.

The PROACT 1 readout will assess the rate of change in estimated kidney filtration, with approximately 320 patients expected in the efficacy analysis. ProKidney anticipates full enrollment for the confirmatory analysis in Q1 2027 with over 500 patients, up from 470; confirmatory results are expected in 2H 2029.

Third-quarter net loss before noncontrolling interest widened to $51.793 million from $35.843 million a year earlier. Research and development expenses rose to $40.845 million from $26.821 million. Cash, cash equivalents and marketable securities totaled $141.9 million, versus $181.6 million at June 30, 2026. The company expects funding to support operations into mid-2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

ProKidney (PROK) will host a virtual expert event on October 27, 2026, to discuss rilparencel research and provide a corporate update. The event begins at 10:30 AM ET. Katherine Tuttle, MD, will join management to discuss research presented at ASN Kidney Week 2026 on how rilparencel works and its potential role in advanced chronic kidney disease and type 2 diabetes.

Research and development head Anthony Conway, PhD, will review the findings, while Tuttle will offer a clinical perspective on treatment needs. A live question-and-answer session will follow the presentations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.69%
Tags
none
-
Rhea-AI Summary

ProKidney (PROK) will present eight abstracts at the American Society of Nephrology’s Kidney Week, held October 21–25, 2026, in Denver.

The program includes one oral presentation and seven posters. Seven abstracts cover chronic kidney disease models and rilparencel drug product characterization. The company describes these studies as supporting multiple mechanisms of action. One clinical abstract presents a pooled Phase 2 analysis of patients meeting key PROACT 1 eligibility criteria; ProKidney says it continues to indicate a favorable safety profile and kidney function stabilization in patients with advanced chronic kidney disease and type 2 diabetes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.69%
Tags
none
Rhea-AI Summary

ProKidney (PROK) will present eight rilparencel abstracts at the American Society of Nephrology’s Kidney Week, held October 21–25, 2026, in Denver.

The program includes one oral presentation. Seven abstracts cover chronic kidney disease (CKD) models and drug product characterization. ProKidney says these findings support a mechanism involving multiple biological processes. One clinical abstract presents a new pooled Phase 2 analysis of patients meeting key PROACT 1 inclusion criteria. The company says the analysis continues to indicate a strong safety profile and kidney function stabilization in patients with advanced CKD and type 2 diabetes. Rilparencel remains under evaluation in the ongoing Phase 3 PROACT 1 study.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.58%
Tags
none
-
Rhea-AI Summary

ProKidney (Nasdaq: PROK) reported second quarter 2026 results and progress on its lead cell therapy, rilparencel, for advanced chronic kidney disease with type 2 diabetes. The company completed enrollment of patients contributing to the Phase 3 PROACT 1 accelerated approval efficacy analysis, expected to include about 320 patients and use annualized eGFR slope as a surrogate endpoint, with topline data anticipated in Q2 2027. Full enrollment of approximately 470 patients for the confirmatory time‑to‑event analysis remains on track for the second half of 2026, with topline results expected in the second half of 2029.

ProKidney ended Q2 2026 with $181.6 million in cash, cash equivalents and marketable securities, which the company says should fund operations into mid‑2027. Q2 2026 research and development expenses were $36.1 million versus $25.9 million a year earlier, general and administrative expenses were $12.4 million versus $14.0 million, and net loss before noncontrolling interest was $46.4 million versus $37.0 million. The company also appointed Kenneth Locke as Chief Technical Officer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.73%
Tags
-
Rhea-AI Summary

ProKidney (Nasdaq: PROK) appointed Kenneth Locke as Chief Technical Officer as it advances toward potential commercialization of rilparencel.

Locke brings over 25 years of CMC and supply chain experience from roles at Carisma Therapeutics, Celgene/Bristol Myers Squibb, and Novartis.

His responsibilities will support ProKidney’s Phase 3 program and anticipated pivotal topline readout in Q2 2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.70%
Tags
none
Rhea-AI Summary

ProKidney (Nasdaq: PROK) reported Q1 2026 results and CKD program progress. The company remains on track to complete enrollment for the Phase 3 PROACT 1 surrogate eGFR endpoint in mid-2026, with pivotal topline data expected in Q2 2027.

ProKidney ended Q1 2026 with $224.9 million in cash, cash equivalents and marketable securities, which it expects will fund operations into mid-2027. Phase 2 REGEN-007 results, including a 4.6 mL/min/1.73m² eGFR slope improvement in Group 1, were published in CJASN.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.92%
Tags
-
Rhea-AI Summary

ProKidney (Nasdaq: PROK) appointed Greg Madison as Chief Commercial Officer on March 25, 2026. Mr. Madison brings more than two decades of commercial and executive biopharma experience, with prior CEO roles and deep nephrology expertise.

He will lead commercial strategy as ProKidney advances rilparencel toward potential commercialization, leveraging prior product launches and business development experience.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.28%
Tags
none
-
Rhea-AI Summary

ProKidney (Nasdaq: PROK) reported full-year 2025 results and business highlights on March 18, 2026. Key points: $270.0M cash and marketable securities at year-end; positive Phase 2 REGEN-007 data; FDA alignment on an accelerated approval pathway using eGFR slope; Phase 3 PROACT 1 enrollment accelerating with pivotal readout expected Q2 2027.

Management expects existing cash to fund operations into mid-2027 and plans BLA submission in Q4 2027 with potential approval and commercial launch in 2H 2028.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.25%
Tags
Rhea-AI Summary

ProKidney (Nasdaq: PROK) announced that CEO Bruce Culleton, M.D. will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 8:15am PST.

The management team will host one-on-one meetings during the event. A live webcast will be available via the company’s Investor Relations "Events" page and at www.prokidney.com. A replay will be accessible for 30 days after the presentation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.14%
Tags
none

FAQ

What is the current stock price of ProKidney (PROK)?

ProKidney (PROK) last closed at $1.05.

What is the market cap of ProKidney (PROK)?

The market cap of ProKidney (PROK) is approximately $218.4M.